Wyeth: Paint by numbers

One of the presumed advantages of big pharma's size is that it can take multiple shots on goal, but one of the downsides of large organizations is lack of efficiency. Wyeth has upped its R&D throughput since 2000 through the simple expedient of demanding that its scientists come up with the number of compounds required to keep the pipeline full.

Whether this will translate into more marketed products remains to be seen. But for four consecutive years, WYE's research group has presented 12 compounds for clinical development per year, compared to three

Read the full 925 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE